Tecvayli, also known by its drug name teclistamab-cqyv, is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for treating relapsed or refractory multiple myeloma in adults who have already tried at least four lines of therapy. These previous therapies must include:

- A proteasome inhibitor
- Show Full Answer

Tecvayli, also known by its drug name teclistamab-cqyv, is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for treating relapsed or refractory multiple myeloma in adults who have already tried at least four lines of therapy. These previous therapies must include:

- A proteasome inhibitor
- An immunomodulatory agent
- An anti-CD38 monoclonal antibody

How Tecvayli Works:
- Type: Bispecific T-cell engager
- Mechanism: Targets the B-cell maturation antigen (BCMA) on B cells (including myeloma cells) and the CD3 protein on T cells. This prompts T cells to kill myeloma cells.

Administration:
- Form: Subcutaneous (under the skin) injection
- Frequency: Once a week after initial loading doses

Common Side Effects:
- Cytokine release syndrome (CRS)
- Fever
- Injection site reactions
- Fatigue
- Upper respiratory tract infections
- Nausea
- Headache
- Pneumonia
- Diarrhea
- Pain in muscles, bones, or joints

Serious Side Effects:
- Severe or life-threatening liver damage and infections
- Hypersensitivity reactions
- Fetal harm

For more details, you can visit the Tecvayli page on MyMyelomaTeam or the official Tecvayli website by Janssen Biotech Inc.

 This AI-generated response comes from MyMyelomaTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Tecvayli (Teclistamab-cqyv) for Myeloma | MyMyelomaTeam

What Is BCMA-Targeted Immunotherapy for Multiple Myeloma? | MyMyelomaTeam